The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024) [0.03%]
Lynch综合征易感基因MLH1、MSH2、MSH6、PMS2和EPCAM大片段缺失的胚系突变携带者的临床实践指南(2024 V4)
J Novotný,D Cibula,V Curtisová et al.
J Novotný et al.
The guidelines for clinical practice for carriers of pathogenic variants in clinically relevant genes predisposing to Lynch syndrome and colorectal cancer define the steps of primary and secondary prevention that should be provided to the i...
Viral pneumonia in a patient treated with pembrolizumab - similarity with immune-related pneumonitis [0.03%]
派姆单抗治疗患者的病毒性肺炎与免疫相关性肺炎的相似性
J Podhorec,L Jakubíková,O Bílek et al.
J Podhorec et al.
Background: Immunotherapy is one of the fundamental treatment modalities, especially in the treatment of metastatic non-small cell lung carcinoma, but it is also applied in neoadjuvant, or adjuvant therapy. A certain limi...
Long-term control by immune checkpoint inhibitors in a lung cancer patient with chronic kidney disease [0.03%]
免疫检查点抑制剂长期控制一例慢性肾病肺癌患者
H Matsumoto,Y Maezawa,G Ohara et al.
H Matsumoto et al.
Background: Immune checkpoint inhibitor (ICI) therapy has brought about a revolutionary advance in the treatment of advanced non-small cell lung cancer (NSCLC). Not a few patients with NSCLC have comorbid diseases. In pat...
Total neoadjuvant therapy involving checkpoint inhibitors in locally advanced MSI/dMMR rectal cancer - a case report [0.03%]
局部晚期MSI/dMMR直肠癌全程新辅助免疫治疗一例报告
S Křivonosková,A Opluštilová,M Levý et al.
S Křivonosková et al.
Background: Typically, the management of locally advanced rectal cancer consists of neoadjuvant chemoradiotherapy, followed by surgery and adjuvant chemotherapy. In addition to neoadjuvant chemoradiotherapy, total neoadju...
Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months… [0.03%]
利妥昔单抗、环磷酰胺和地塞米松治疗后，使用利妥昔单抗和地塞米松维持缓解，患者的腹膜后纤维化在4个月时病灶明显缩小、FDG代谢恢复正常
A Čermák,J Foukal,Z Řehák et al.
A Čermák et al.
Background: Idiopathic retroperitoneal fibrosis is characterized by the development of inflammatory infiltrates with marked fibrosis along the large retroperitoneal vessels. Rituximab in combination with glucocorticoids c...
L Melich,J Werle,M Fořtová et al.
L Melich et al.
Background: Malignant liver tumors are highly aggressive with a poor prognosis. Metalothionein (MT) is a low-molecular intracellular protein, whose primary function is to regulate the homeostasis of heavy metals in many o...
Accelerated radiotherapy in the treatment of anal squamous cell carcinoma - a single institution retrospective evaluation [0.03%]
加速放疗在肛鳞细胞癌治疗中的应用——单中心回顾性分析
Z Pechačová,R Lohynská,Š Šantrůčková et al.
Z Pechačová et al.
Background: The goal of treatment for anal squamous cell carcinoma (ASCC) is to preserve a functional anal sphincter and maintain the best quality of life. Surgical excision is reserved only for very early stages, and con...
Gemcitabine/nab-paclitaxel in first line treatment of advanced pancreatic cancer - head-to-head comparison with the mFOLFIRINOX regimen [0.03%]
吉西他滨/白蛋白结合型紫杉醇与mFOLFIRINOX方案一线治疗晚期胰腺导管癌的比较研究
J Tomášek
J Tomášek
Metastatic pancreatic ductal carcinoma (mPDAC) is one of the most lethal malignancies. The European Society for Medical Oncology (ESMO) guidelines recommend a gemcitabine doublet + nab-paclitaxel (Gem/Nab-P) or a modified FOLFIRINOX regimen...
The dyslipidemic effect of cytostatics in the treatment of early breast cancer as a serious risk factor of cardiovascular diseases [0.03%]
细胞毒性药物治疗早期乳腺癌的血脂紊乱效应作为一个严重的心血管疾病危险因素
L Rušinová,M Kozárová,Z Kozelová et al.
L Rušinová et al.
Backround: The development of highly effective anti-cancer therapies over the past several decades has dramatically changed the situation of patients with malignant tumor disease, who currently achieve a high rate of cure...
Treatment of tobacco dependence in cancer patients - Recommendations of the Section of Supportive Treatment and Care and the Section of Preventive Oncology of the Czech Cancer Society of the Czech Medical Association of J. E. Purkyně, Working Group for t… [0.03%]
癌症患者烟草依赖的治疗-捷克抗癌协会捷克耶·恩斯特·普尔凯尼医学协会支持治疗和护理部门和预防肿瘤学工作组的意见书摘要
K Zvolská,E Králíková,S Vokurka et al.
K Zvolská et al.
Smoking is a significant risk factor for the development of many cancers. In addition, after a cancer dia-gnosis, it also has an adverse effect on survival, the course and effectiveness of cancer treatment and quality of life, and increases...